Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance
Genes · 2023
DOI: 10.3390/genes14122227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Spyridon N Vasilopoulos und 4 weiteren Autor:innen. Beteiligte Einrichtung: DNA Damage Laboratory, Physics Department, School of Applied Mathematical and Physical Sciences, National Technical University of Athens (NTUA), Zogr…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BIOSPHERE, European Partnership on Metrology, European Union’s Horizon Europe Research and Innovation Programme.
Abstract (Originalsprache)
Ionizing radiation can induce different types of DNA lesions, leading to genomic instability and ultimately cell death. Radiation therapy or radiotherapy, a major modality in cancer treatment, harnesses the genotoxic potential of radiation to target and destroy cancer cells. Nevertheless, cancer cells have the capacity to develop resistance to radiation treatment (radioresistance), which poses a major obstacle in the effective management of cancer. It has been shown that administration of platinum-based drugs to cancer patients can increase tumor radiosensitivity, but despite this, it is associated with severe adverse effects. Several lines of evidence support that activation of the DNA damage response and repair machinery in the irradiated cancer cells enhances radioresistance and cellular survival through the efficient repair of DNA lesions. Therefore, targeting of key DNA damage repair factors would render cancer cells vulnerable to the irradiation effects, increase cancer cell killing, and reduce the risk of side effects on healthy tissue. Herein, we have employed a computer-aided drug design approach for generating ab initio a chemical compound with drug-like properties potentially targeting two proteins implicated in multiple DNA repair pathways. The findings of this study could be taken into consideration in clinical decision-making in terms of co-administering radiation with DNA damage repair factor-based drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- DNA Damage Laboratory, Physics Department, School of Applied Mathematical and Physical Sciences, National Technical University of Athens (NTUA), Zografou Campus, 15780 Athens, Greece.
- Department of Science and Mathematics, Deree-The American College of Greece, 6 Gravias Street, 15342 Athens, Greece.
- Izmir Biomedicine and Genome Center (IBG), 35340 Izmir, Turkey.
- Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, 35340 Izmir, Turkey.
- Department of Molecular Biology and Genetics, Faculty of Life and Natural Science, Abdullah Gül University, 38080 Kayseri, Turkey.
ORCID-Profile: Spyridon N Vasilopoulos, Hüseyin Güner, Athanasia Pavlopoulou, Alexandros G Georgakilas
Förderung
- BIOSPHERE
- European Partnership on Metrology
- European Union’s Horizon Europe Research and Innovation Programme
- COST (European Cooperation in Science and Technology)
Zitieren
APA
Vasilopoulos, S. N., Güner, H., Uça Apaydın, M., Pavlopoulou, A., & Georgakilas, A. G. (2023). Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance. Genes. https://doi.org/10.3390/genes14122227
Vancouver
Vasilopoulos SN, Güner H, Uça Apaydın M, Pavlopoulou A, Georgakilas AG. Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance. Genes. 2023. doi:10.3390/genes14122227
BibTeX
@article{Vasilopoulos2023,
author = {Vasilopoulos, Spyridon N and Güner, Hüseyin and Uça Apaydın, Merve and Pavlopoulou, Athanasia and Georgakilas, Alexandros G},
title = {Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14122227}
}
EUVIMED